
Par Pharmaceutical Companies, Inc.’s wholly-owned subsidiary, Kali Laboratories, Inc., has received final approval from the USFDA for its Abbreviated New Drug Application for tranylcypromine sulfate tablets, 10 mg.
Tranylcypromine Sulfate Tablets, 10 mg is the generic version of GlaxoSmithKline's Parnate® for the treatment of depression.
Shipment of the product begins immediately, following approval.
Source: PR Newswire



.jpg)



Comment Preview